Followup of Men with PI-RADS^TM 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Reply

Xiaosong Meng^{1

2}, Brian Chao¹, Fei Chen³, Richard Huang¹, Samir S Taneja^{1

4

5}, Fang-Ming Deng³

Affiliations

¹ Department of Urology, Division of Urologic Oncology, NYU Langone Health, New York, New York.
² Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
³ Department of Pathology, NYU Langone Health, New York, New York.
⁴ Department of Radiology, NYU Langone Health, New York, New York.
⁵ Department of Biomedical Engineering, NYU Langone Health, New York, New York.

Comment

Xiaosong Meng et al. J Urol. 2021 May.

. 2021 May;205(5):1528-1529.

doi: 10.1097/JU.0000000000001590. Epub 2020 Dec 22.

Xiaosong Meng^{1

2}, Brian Chao¹, Fei Chen³, Richard Huang¹, Samir S Taneja^{1

4

5}, Fang-Ming Deng³

¹ Department of Urology, Division of Urologic Oncology, NYU Langone Health, New York, New York.
² Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
³ Department of Pathology, NYU Langone Health, New York, New York.
⁴ Department of Radiology, NYU Langone Health, New York, New York.
⁵ Department of Biomedical Engineering, NYU Langone Health, New York, New York.

No abstract available

Comment on

Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
Meng X, Chao B, Chen F, Huang R, Taneja SS, Deng FM. Meng X, et al. J Urol. 2021 Mar;205(3):748-754. doi: 10.1097/JU.0000000000001424. Epub 2020 Oct 20. J Urol. 2021. PMID: 33080145